An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT
Early relapse (ER) following Autologous Hematopoietic Cell Transplantation (AHCT) confers a poor prognosis. We therefore developed a novel scoring system to predict ER. A total of 14,367 AHCT-1 patients were transplanted between 2014 and 2019, and were conditioned with Melphalan 200 mg/m 2 (Mel200)...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2023-08, Vol.58 (8), p.916-923 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 923 |
|---|---|
| container_issue | 8 |
| container_start_page | 916 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 58 |
| creator | Beksac, Meral Iacobelli, Simona Koster, Linda Cornelissen, Jan Griskevicius, Laimonas Rabin, Neil K. Stoppa, Anne Marie Meijer, Ellen Mear, Jean-Baptiste Zeerleder, Sacha Mayer, Jiri Fenk, Roland Fegueux, Nathalie Chevallier, Patrice Konirova, Eva Snowden, John A. Engelhardt, Monika Orchard, Kim Hulin, Cyrille Schaap, Nicolaas Sossa, Claudia Elmaagacli, Ahmet McLornan, Donal P. Hayden, Patrick J. Schönland, Stefan Yakoub-Agha, Ibrahim |
| description | Early relapse (ER) following Autologous Hematopoietic Cell Transplantation (AHCT) confers a poor prognosis. We therefore developed a novel scoring system to predict ER. A total of 14,367 AHCT-1 patients were transplanted between 2014 and 2019, and were conditioned with Melphalan 200 mg/m
2
(Mel200) (
n
= 7228; 2014–2017) (training cohort); Mel200 (
n
= 5616; 2018–2019) or Mel140 (
n
= 1523; 2018–2019) (validation cohorts). PFS-12 and the Cumulative Incidence of Relapse at 12 months were 84.1% and 14.7% (training Mel200), 87.2% and 11.6% (validation Mel200), and 80.3% and 16.9% (validation Mel140), respectively. The points in the risk score were: 0, 1,2 for ISS stages I, II, and III; Disease status: 0 (CR/VGPR); 1 (PR); 2 (SD/MR); 4 (Relapse/Progression); and 1 for Karnofsky ≤ 70. The distribution of scores: 0 (24%), 1 (33.9%), 2 (29.6 %), 3 (9.5%), and ≥4 (2.7%). The score separated PFS-12, with the lowest risk group (
n
= 1752) having a PFS-12 of 91.7% and the highest risk group (
n
= 195) 57.1%. This also applied in cytogenetically high-risk patients. If the pre-score baseline risks are 15% (standard risk) and 25% (high-risk), a score of ≥4 confers calculated risks of 38% and 54%, respectively. This novel EBMT ER score, therefore, allows for the identification of five discrete prognostic groups. |
| doi_str_mv | 10.1038/s41409-023-01999-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04520275v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2845354426</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-e89699851ca5c2a5c5bea15144f1132f25170dd64211be5ffb8805b872146a8e3</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS0EokPhBVggS2xgEfBvJmY3VIUiDWJT1paT3My4OHawnaI8Ba-Mh5QisWBhWbr-fHyOD0LPKXlDCW_eJkEFURVhvCJUKVXRB2hDxbauJK_lQ7QhrG4qzmt1hp6kdEMIFYLIx-iMb2lNlGAb9HPnMZjoFjyFlKscjU-TMz7jCM5MCfAUobddtsHj1IUI2Ho8zi7byQEeF3BhNO-wwc7EA-AuHEPMOOW5X_AQw4jzsUyPMXjb4dE4e_DGdxYS_hHiN-sPeDIxLzgM-PL95-un6NFgXIJnd_s5-vrh8vriqtp_-fjpYrevuhI5V9CoWqlG0s7IjpUlWzBUlnwDpZwNTNIt6ftaMEpbkMPQNg2RbbNlVNSmAX6OXq-6R-P0FO1o4qKDsfpqt9enGRGSEbaVt7Swr1Z2iuH7DCnr0aYOXPkmCHPSrKFU8eKoLujLf9CbMEdfkhRKSC6FYCeKrVQXQ0oRhnsHlOhTtXqtVpdq9e9q9cnFizvpuR2hv7_yp8sC8BVI5cgfIP59-z-yvwDG8a74</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2845354426</pqid></control><display><type>article</type><title>An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>Beksac, Meral ; Iacobelli, Simona ; Koster, Linda ; Cornelissen, Jan ; Griskevicius, Laimonas ; Rabin, Neil K. ; Stoppa, Anne Marie ; Meijer, Ellen ; Mear, Jean-Baptiste ; Zeerleder, Sacha ; Mayer, Jiri ; Fenk, Roland ; Fegueux, Nathalie ; Chevallier, Patrice ; Konirova, Eva ; Snowden, John A. ; Engelhardt, Monika ; Orchard, Kim ; Hulin, Cyrille ; Schaap, Nicolaas ; Sossa, Claudia ; Elmaagacli, Ahmet ; McLornan, Donal P. ; Hayden, Patrick J. ; Schönland, Stefan ; Yakoub-Agha, Ibrahim</creator><creatorcontrib>Beksac, Meral ; Iacobelli, Simona ; Koster, Linda ; Cornelissen, Jan ; Griskevicius, Laimonas ; Rabin, Neil K. ; Stoppa, Anne Marie ; Meijer, Ellen ; Mear, Jean-Baptiste ; Zeerleder, Sacha ; Mayer, Jiri ; Fenk, Roland ; Fegueux, Nathalie ; Chevallier, Patrice ; Konirova, Eva ; Snowden, John A. ; Engelhardt, Monika ; Orchard, Kim ; Hulin, Cyrille ; Schaap, Nicolaas ; Sossa, Claudia ; Elmaagacli, Ahmet ; McLornan, Donal P. ; Hayden, Patrick J. ; Schönland, Stefan ; Yakoub-Agha, Ibrahim</creatorcontrib><description>Early relapse (ER) following Autologous Hematopoietic Cell Transplantation (AHCT) confers a poor prognosis. We therefore developed a novel scoring system to predict ER. A total of 14,367 AHCT-1 patients were transplanted between 2014 and 2019, and were conditioned with Melphalan 200 mg/m
2
(Mel200) (
n
= 7228; 2014–2017) (training cohort); Mel200 (
n
= 5616; 2018–2019) or Mel140 (
n
= 1523; 2018–2019) (validation cohorts). PFS-12 and the Cumulative Incidence of Relapse at 12 months were 84.1% and 14.7% (training Mel200), 87.2% and 11.6% (validation Mel200), and 80.3% and 16.9% (validation Mel140), respectively. The points in the risk score were: 0, 1,2 for ISS stages I, II, and III; Disease status: 0 (CR/VGPR); 1 (PR); 2 (SD/MR); 4 (Relapse/Progression); and 1 for Karnofsky ≤ 70. The distribution of scores: 0 (24%), 1 (33.9%), 2 (29.6 %), 3 (9.5%), and ≥4 (2.7%). The score separated PFS-12, with the lowest risk group (
n
= 1752) having a PFS-12 of 91.7% and the highest risk group (
n
= 195) 57.1%. This also applied in cytogenetically high-risk patients. If the pre-score baseline risks are 15% (standard risk) and 25% (high-risk), a score of ≥4 confers calculated risks of 38% and 54%, respectively. This novel EBMT ER score, therefore, allows for the identification of five discrete prognostic groups.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/s41409-023-01999-1</identifier><identifier>PMID: 37160942</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67/1990/804 ; 692/699/1541/1990/804 ; Cell Biology ; Cohort analysis ; Hematology ; Hematopoietic stem cells ; Internal Medicine ; Life Sciences ; Malignancy ; Medicine ; Medicine & Public Health ; Melphalan ; Multiple myeloma ; Public Health ; Risk ; Risk groups ; Stem cell transplantation ; Stem Cells ; Training ; Transplantation ; Transplants & implants</subject><ispartof>Bone marrow transplantation (Basingstoke), 2023-08, Vol.58 (8), p.916-923</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited 2023. corrected publication 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer Nature Limited.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-e89699851ca5c2a5c5bea15144f1132f25170dd64211be5ffb8805b872146a8e3</citedby><cites>FETCH-LOGICAL-c409t-e89699851ca5c2a5c5bea15144f1132f25170dd64211be5ffb8805b872146a8e3</cites><orcidid>0000-0003-1224-091X ; 0000-0002-4853-5579 ; 0000-0003-0405-1676 ; 0000-0003-1374-4503 ; 0000-0003-1797-8657 ; 0000-0001-6819-3476 ; 0000-0003-4524-8782 ; 0000-0003-3142-5581</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41409-023-01999-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41409-023-01999-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37160942$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-lille.fr/hal-04520275$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Beksac, Meral</creatorcontrib><creatorcontrib>Iacobelli, Simona</creatorcontrib><creatorcontrib>Koster, Linda</creatorcontrib><creatorcontrib>Cornelissen, Jan</creatorcontrib><creatorcontrib>Griskevicius, Laimonas</creatorcontrib><creatorcontrib>Rabin, Neil K.</creatorcontrib><creatorcontrib>Stoppa, Anne Marie</creatorcontrib><creatorcontrib>Meijer, Ellen</creatorcontrib><creatorcontrib>Mear, Jean-Baptiste</creatorcontrib><creatorcontrib>Zeerleder, Sacha</creatorcontrib><creatorcontrib>Mayer, Jiri</creatorcontrib><creatorcontrib>Fenk, Roland</creatorcontrib><creatorcontrib>Fegueux, Nathalie</creatorcontrib><creatorcontrib>Chevallier, Patrice</creatorcontrib><creatorcontrib>Konirova, Eva</creatorcontrib><creatorcontrib>Snowden, John A.</creatorcontrib><creatorcontrib>Engelhardt, Monika</creatorcontrib><creatorcontrib>Orchard, Kim</creatorcontrib><creatorcontrib>Hulin, Cyrille</creatorcontrib><creatorcontrib>Schaap, Nicolaas</creatorcontrib><creatorcontrib>Sossa, Claudia</creatorcontrib><creatorcontrib>Elmaagacli, Ahmet</creatorcontrib><creatorcontrib>McLornan, Donal P.</creatorcontrib><creatorcontrib>Hayden, Patrick J.</creatorcontrib><creatorcontrib>Schönland, Stefan</creatorcontrib><creatorcontrib>Yakoub-Agha, Ibrahim</creatorcontrib><title>An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>Early relapse (ER) following Autologous Hematopoietic Cell Transplantation (AHCT) confers a poor prognosis. We therefore developed a novel scoring system to predict ER. A total of 14,367 AHCT-1 patients were transplanted between 2014 and 2019, and were conditioned with Melphalan 200 mg/m
2
(Mel200) (
n
= 7228; 2014–2017) (training cohort); Mel200 (
n
= 5616; 2018–2019) or Mel140 (
n
= 1523; 2018–2019) (validation cohorts). PFS-12 and the Cumulative Incidence of Relapse at 12 months were 84.1% and 14.7% (training Mel200), 87.2% and 11.6% (validation Mel200), and 80.3% and 16.9% (validation Mel140), respectively. The points in the risk score were: 0, 1,2 for ISS stages I, II, and III; Disease status: 0 (CR/VGPR); 1 (PR); 2 (SD/MR); 4 (Relapse/Progression); and 1 for Karnofsky ≤ 70. The distribution of scores: 0 (24%), 1 (33.9%), 2 (29.6 %), 3 (9.5%), and ≥4 (2.7%). The score separated PFS-12, with the lowest risk group (
n
= 1752) having a PFS-12 of 91.7% and the highest risk group (
n
= 195) 57.1%. This also applied in cytogenetically high-risk patients. If the pre-score baseline risks are 15% (standard risk) and 25% (high-risk), a score of ≥4 confers calculated risks of 38% and 54%, respectively. This novel EBMT ER score, therefore, allows for the identification of five discrete prognostic groups.</description><subject>631/67/1990/804</subject><subject>692/699/1541/1990/804</subject><subject>Cell Biology</subject><subject>Cohort analysis</subject><subject>Hematology</subject><subject>Hematopoietic stem cells</subject><subject>Internal Medicine</subject><subject>Life Sciences</subject><subject>Malignancy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Melphalan</subject><subject>Multiple myeloma</subject><subject>Public Health</subject><subject>Risk</subject><subject>Risk groups</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Training</subject><subject>Transplantation</subject><subject>Transplants & implants</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kc1u1DAUhS0EokPhBVggS2xgEfBvJmY3VIUiDWJT1paT3My4OHawnaI8Ba-Mh5QisWBhWbr-fHyOD0LPKXlDCW_eJkEFURVhvCJUKVXRB2hDxbauJK_lQ7QhrG4qzmt1hp6kdEMIFYLIx-iMb2lNlGAb9HPnMZjoFjyFlKscjU-TMz7jCM5MCfAUobddtsHj1IUI2Ho8zi7byQEeF3BhNO-wwc7EA-AuHEPMOOW5X_AQw4jzsUyPMXjb4dE4e_DGdxYS_hHiN-sPeDIxLzgM-PL95-un6NFgXIJnd_s5-vrh8vriqtp_-fjpYrevuhI5V9CoWqlG0s7IjpUlWzBUlnwDpZwNTNIt6ftaMEpbkMPQNg2RbbNlVNSmAX6OXq-6R-P0FO1o4qKDsfpqt9enGRGSEbaVt7Swr1Z2iuH7DCnr0aYOXPkmCHPSrKFU8eKoLujLf9CbMEdfkhRKSC6FYCeKrVQXQ0oRhnsHlOhTtXqtVpdq9e9q9cnFizvpuR2hv7_yp8sC8BVI5cgfIP59-z-yvwDG8a74</recordid><startdate>20230801</startdate><enddate>20230801</enddate><creator>Beksac, Meral</creator><creator>Iacobelli, Simona</creator><creator>Koster, Linda</creator><creator>Cornelissen, Jan</creator><creator>Griskevicius, Laimonas</creator><creator>Rabin, Neil K.</creator><creator>Stoppa, Anne Marie</creator><creator>Meijer, Ellen</creator><creator>Mear, Jean-Baptiste</creator><creator>Zeerleder, Sacha</creator><creator>Mayer, Jiri</creator><creator>Fenk, Roland</creator><creator>Fegueux, Nathalie</creator><creator>Chevallier, Patrice</creator><creator>Konirova, Eva</creator><creator>Snowden, John A.</creator><creator>Engelhardt, Monika</creator><creator>Orchard, Kim</creator><creator>Hulin, Cyrille</creator><creator>Schaap, Nicolaas</creator><creator>Sossa, Claudia</creator><creator>Elmaagacli, Ahmet</creator><creator>McLornan, Donal P.</creator><creator>Hayden, Patrick J.</creator><creator>Schönland, Stefan</creator><creator>Yakoub-Agha, Ibrahim</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-1224-091X</orcidid><orcidid>https://orcid.org/0000-0002-4853-5579</orcidid><orcidid>https://orcid.org/0000-0003-0405-1676</orcidid><orcidid>https://orcid.org/0000-0003-1374-4503</orcidid><orcidid>https://orcid.org/0000-0003-1797-8657</orcidid><orcidid>https://orcid.org/0000-0001-6819-3476</orcidid><orcidid>https://orcid.org/0000-0003-4524-8782</orcidid><orcidid>https://orcid.org/0000-0003-3142-5581</orcidid></search><sort><creationdate>20230801</creationdate><title>An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT</title><author>Beksac, Meral ; Iacobelli, Simona ; Koster, Linda ; Cornelissen, Jan ; Griskevicius, Laimonas ; Rabin, Neil K. ; Stoppa, Anne Marie ; Meijer, Ellen ; Mear, Jean-Baptiste ; Zeerleder, Sacha ; Mayer, Jiri ; Fenk, Roland ; Fegueux, Nathalie ; Chevallier, Patrice ; Konirova, Eva ; Snowden, John A. ; Engelhardt, Monika ; Orchard, Kim ; Hulin, Cyrille ; Schaap, Nicolaas ; Sossa, Claudia ; Elmaagacli, Ahmet ; McLornan, Donal P. ; Hayden, Patrick J. ; Schönland, Stefan ; Yakoub-Agha, Ibrahim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-e89699851ca5c2a5c5bea15144f1132f25170dd64211be5ffb8805b872146a8e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>631/67/1990/804</topic><topic>692/699/1541/1990/804</topic><topic>Cell Biology</topic><topic>Cohort analysis</topic><topic>Hematology</topic><topic>Hematopoietic stem cells</topic><topic>Internal Medicine</topic><topic>Life Sciences</topic><topic>Malignancy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Melphalan</topic><topic>Multiple myeloma</topic><topic>Public Health</topic><topic>Risk</topic><topic>Risk groups</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Training</topic><topic>Transplantation</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Beksac, Meral</creatorcontrib><creatorcontrib>Iacobelli, Simona</creatorcontrib><creatorcontrib>Koster, Linda</creatorcontrib><creatorcontrib>Cornelissen, Jan</creatorcontrib><creatorcontrib>Griskevicius, Laimonas</creatorcontrib><creatorcontrib>Rabin, Neil K.</creatorcontrib><creatorcontrib>Stoppa, Anne Marie</creatorcontrib><creatorcontrib>Meijer, Ellen</creatorcontrib><creatorcontrib>Mear, Jean-Baptiste</creatorcontrib><creatorcontrib>Zeerleder, Sacha</creatorcontrib><creatorcontrib>Mayer, Jiri</creatorcontrib><creatorcontrib>Fenk, Roland</creatorcontrib><creatorcontrib>Fegueux, Nathalie</creatorcontrib><creatorcontrib>Chevallier, Patrice</creatorcontrib><creatorcontrib>Konirova, Eva</creatorcontrib><creatorcontrib>Snowden, John A.</creatorcontrib><creatorcontrib>Engelhardt, Monika</creatorcontrib><creatorcontrib>Orchard, Kim</creatorcontrib><creatorcontrib>Hulin, Cyrille</creatorcontrib><creatorcontrib>Schaap, Nicolaas</creatorcontrib><creatorcontrib>Sossa, Claudia</creatorcontrib><creatorcontrib>Elmaagacli, Ahmet</creatorcontrib><creatorcontrib>McLornan, Donal P.</creatorcontrib><creatorcontrib>Hayden, Patrick J.</creatorcontrib><creatorcontrib>Schönland, Stefan</creatorcontrib><creatorcontrib>Yakoub-Agha, Ibrahim</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Beksac, Meral</au><au>Iacobelli, Simona</au><au>Koster, Linda</au><au>Cornelissen, Jan</au><au>Griskevicius, Laimonas</au><au>Rabin, Neil K.</au><au>Stoppa, Anne Marie</au><au>Meijer, Ellen</au><au>Mear, Jean-Baptiste</au><au>Zeerleder, Sacha</au><au>Mayer, Jiri</au><au>Fenk, Roland</au><au>Fegueux, Nathalie</au><au>Chevallier, Patrice</au><au>Konirova, Eva</au><au>Snowden, John A.</au><au>Engelhardt, Monika</au><au>Orchard, Kim</au><au>Hulin, Cyrille</au><au>Schaap, Nicolaas</au><au>Sossa, Claudia</au><au>Elmaagacli, Ahmet</au><au>McLornan, Donal P.</au><au>Hayden, Patrick J.</au><au>Schönland, Stefan</au><au>Yakoub-Agha, Ibrahim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2023-08-01</date><risdate>2023</risdate><volume>58</volume><issue>8</issue><spage>916</spage><epage>923</epage><pages>916-923</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><abstract>Early relapse (ER) following Autologous Hematopoietic Cell Transplantation (AHCT) confers a poor prognosis. We therefore developed a novel scoring system to predict ER. A total of 14,367 AHCT-1 patients were transplanted between 2014 and 2019, and were conditioned with Melphalan 200 mg/m
2
(Mel200) (
n
= 7228; 2014–2017) (training cohort); Mel200 (
n
= 5616; 2018–2019) or Mel140 (
n
= 1523; 2018–2019) (validation cohorts). PFS-12 and the Cumulative Incidence of Relapse at 12 months were 84.1% and 14.7% (training Mel200), 87.2% and 11.6% (validation Mel200), and 80.3% and 16.9% (validation Mel140), respectively. The points in the risk score were: 0, 1,2 for ISS stages I, II, and III; Disease status: 0 (CR/VGPR); 1 (PR); 2 (SD/MR); 4 (Relapse/Progression); and 1 for Karnofsky ≤ 70. The distribution of scores: 0 (24%), 1 (33.9%), 2 (29.6 %), 3 (9.5%), and ≥4 (2.7%). The score separated PFS-12, with the lowest risk group (
n
= 1752) having a PFS-12 of 91.7% and the highest risk group (
n
= 195) 57.1%. This also applied in cytogenetically high-risk patients. If the pre-score baseline risks are 15% (standard risk) and 25% (high-risk), a score of ≥4 confers calculated risks of 38% and 54%, respectively. This novel EBMT ER score, therefore, allows for the identification of five discrete prognostic groups.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>37160942</pmid><doi>10.1038/s41409-023-01999-1</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-1224-091X</orcidid><orcidid>https://orcid.org/0000-0002-4853-5579</orcidid><orcidid>https://orcid.org/0000-0003-0405-1676</orcidid><orcidid>https://orcid.org/0000-0003-1374-4503</orcidid><orcidid>https://orcid.org/0000-0003-1797-8657</orcidid><orcidid>https://orcid.org/0000-0001-6819-3476</orcidid><orcidid>https://orcid.org/0000-0003-4524-8782</orcidid><orcidid>https://orcid.org/0000-0003-3142-5581</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2023-08, Vol.58 (8), p.916-923 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04520275v1 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SpringerLink Journals - AutoHoldings |
| subjects | 631/67/1990/804 692/699/1541/1990/804 Cell Biology Cohort analysis Hematology Hematopoietic stem cells Internal Medicine Life Sciences Malignancy Medicine Medicine & Public Health Melphalan Multiple myeloma Public Health Risk Risk groups Stem cell transplantation Stem Cells Training Transplantation Transplants & implants |
| title | An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T04%3A20%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20early%20post-transplant%20relapse%20prediction%20score%20in%20multiple%20myeloma:%20a%20large%20cohort%20study%20from%20the%20chronic%20malignancies%20working%20party%20of%20EBMT&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Beksac,%20Meral&rft.date=2023-08-01&rft.volume=58&rft.issue=8&rft.spage=916&rft.epage=923&rft.pages=916-923&rft.issn=0268-3369&rft.eissn=1476-5365&rft_id=info:doi/10.1038/s41409-023-01999-1&rft_dat=%3Cproquest_hal_p%3E2845354426%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2845354426&rft_id=info:pmid/37160942&rfr_iscdi=true |